Summary Immunotherapy with Mycobacterium w was given, in addition to standard multidrug therapy (MDT) to a lepromatous leprosy (LL) patient with a bacteriological index (BI) of 6. After 15 months of treatment this patient attained bacteriological negativity and clinical inactivity. Histopathologically the patient upgraded to borderline-tuberculoid at 12 months, and at 15 months showed fe atures of nonspecific infiltration in the dermis. The rapid immunological upgrading seen in the patient is highlighted in this paper.
Lepromatous leprosy patients show anergy to react against My cobacterium leprae and its multiplication in skin and peripheral nerves is virtually unchecked as there is an absence of host cell-mediated immunity (CMI).! This case report fo rms part of a large scale ongoing phase II/phase III clinical trials to evaluate the immunotherapeutic and immunoprophylactic potential of an antileprosy vaccine, Mycobacterium w (M. w) . The study is designed to investigate if immunotherapy in the fo rm of a vaccine, based on a cross-reactive mycobacterium, given as an adjunct to chemotherapy is able to induce host CMI and reverse the host anergy to M. leprae. Early results of the immunotherapeutic trials with this vaccine have already been reported.2•3 This case highlights a patient with an initial bacteriological index (BI) of 6 who upgraded immunologically to borderline tuberculoid (BT) and then was completely cleared of bacilli and granuloma in a period of less than 24 pulses of MDT.
Case report
A 55-year-old male patient came with complaints of lesions on trunk and limbs, loss of sensation in hands and fe et and a trophic ulcer on the left fo ot of 18 months duration. He had no previous history of treatment. On examination the patient had papulonodular lesions and erythematous plaques over the face, chest and back and coarse infiltration over the rest of the body ( Figure I ). All nerve trunks were bilaterally involved moderately thick but not tender. The patient had glove and stocking loss of sensation. Slit smears from both eyebrows, earlobes and from two patches on the lower back gave a Clinical scoring was done every 6 months using Ramu's score .4.5 In this scoring system the body is divided into 7 regions, i.e. fa ce, head and neck, right and left upper limbs, chest and abdomen, back and buttock, and right and left lower limbs. Each region is independently scored. A score of one is given to predominantly macular lesions, two to diffuse infiltration, three to few papules or plaques and fo ur to predominantly papulonodular lesions. A score of one to fo ur is thus given to each of the 7 regions. This patients cumulative initial score was 22. The patient was administered a standard multidrug regimen (MDT)6.
In addition to chemotherapy, the patient received vaccine containing I x 109 killed M. win 0· 1 ml normal saline (0,85% NaCI) as first dose, fo llowed by 5 x 108 killed bacilli as subsequent doses given intradermally (i.d.) at 3 monthly intervals. After 2 doses of vaccine and 4 months of regular treatment, the patient defaulted in attending the clinic due to personal problems. After a 7-month lapse, the patient reported to the clinic presenting with a mild Type 1 upgrading reaction. During this period the patient denied having taken any antileprosy treatment. The spot test fo r dapsone (DDSr in urine was negative. The patient was then reviewed for his clinical, bacteriological, histopathological and immunological status. The patients BI had fallen to 2'33, and he had histopathologi cally upgraded to BL. The lepromin reaction was 5 mm at this time and clinical improvement was evidenced by a decrease in clinical score to 15. The patient was managed on nonsteroidal anti-inflammatory drugs (NSAID).
At the end of 12 months of treatment and 4 doses of vaccine, the patient showed notable clinical ( Figure 3 ) and bacteriological improvement. His BI had fa llen to 0·66 and his clinical score was 5. Histopathologically there was an upgrading to BT ( Figure 4 ) and a lepromin reaction showed 7 mm induration (moderately positive). After a further period of3 months of therapy, the patient reached a stage of both bacterial and clinical inactivity. Biopsy from the same skin site revealed only sparse infiltration in the dermis with no evidence of granuloma or AFB. Repeat slit-skin smears over the next 2 months were also negative. In October 1989 this patient was released from treatment after completing 24 pulses. Case progression in terms of lepromin conversion and bacterial fa ll is given in Figure 5 .
Discussion
This case report highlights the immunological upgrading of an LL patients after receiving M. w vaccine.
The reports with MDT alone show that in multi bacillary (MB) cases, the mean BI fa ll is between 0·6 and 1·0 unit per year8. 1t is well documented that patients on chemotherapy do not upgrade immunologically and remain lepromin negative at the end of therapy despite bacteriological negativity. 9 . lo This particular case demonstrated a rapid fa ll in BI (from 6 to 0 in less than 24 months), showed a Mitsuda lepromin conversion (from negativity to 7 mm positivity) and went through a gradual histopathological upgrading from LL to BL to BT and then showed complete subsidence of disease without any undesirable side-effects including nerve damage. Convit et al. have reported immunological upgrading with a vaccine containing killed M. leprae and live BCG. They observed histological upgrading in 71 % patients and soluble antigen (SA) conversion in 38% active LL and BL patients.I I.12 Kaplan et al. have shown faster rates ofBI fall in sites locally injected with interleukin-2. 13 Deo et al. have used ICRC bacillus as an immunotherapeutic vaccine. The vaccine has shown to engender lepromin conversion and clinical upgrading in lepromatous patients. 14 The mechanisms of action of M. w are as yet unclear. The in vitro and animal experimental studies indicate presence in M. w of antigens cross-reactive with M. leprae. 1 5•1 6 These antigens were fo und immunogenic in nature as they evoked DTH type of reaction in both LL and TT patients, when administered intradermally.I7·18 M.w has also shown a good DTH response locally at the vaccination site.
Currently over 320 patients are enrolled in the on going immunotherapeutic trials. Further analysis of results of these cases will help to substantiate the beneficial immunotherapeutic effects of this vaccine.
